The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have launched a consultation into their joint network strategy for the next five years.
The European Medicines Agencies Network Strategy to 2025 is an update of the strategy to 2020, with six key priorities:
- the availability and accessibility of medicines
- data analytics, digital tools and digital transformation
- antimicrobial resistance and other emerging health threats
- supply chain challenges
- the sustainability of the network and operational excellence
“The draft strategy details how the European medicines agencies’ network can continue to enable the supply of safe and effective medicines that meet patients’ needs in the face of challenges posed by ever-accelerating developments in science, medicine, digital technologies, globalisation as well as emerging health threats, such as the COVID-19 pandemic.”
Although there will be a definitive edition of the strategy following the consultation, EMA says that the document will be a “living document”, subject to revisions and improvements as needed.
Find out more about the consultation and draft strategy on the EMA website. A helpful video explains the exercise in more detail. Take part in the consultation through the EU Survey platform. Follow the consultation on MAP’s consultation tracker.